AbstractA series of novel hybrid molecules were designed rationally by connecting an indole moiety with a quinoxaline ring through a linker as potential inhibitors of PDE4. Their design was validated initially in silico by performing docking studies using a representative molecule. Subsequent synthesis of a focused library of related hybrid molecules was accomplished using Pd/CCu mediated coupling-cyclization as a key step. Some of the synthesized compounds showed PDE4 inhibition in vitro and one of them appeared to be promising
In this study, a series of pyrazole derivatives containing 4-phenyl-2-oxazole moiety were designed a...
A number of novel 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles based on a conform...
<p>cAMP, intracellular cyclic adenosine monophosphate, is a ubiquitous second messenger that plays a...
A series of novel hybrid molecules were designed rationally by connecting an indole moiety with a q...
AbstractA series of novel hybrid molecules were designed rationally by connecting an indole moiety w...
The design, synthesis, and biological evaluation of new phosphodiesterase type 4 (PDE4) inhibitors, ...
We report here a new series of quinolines as PDE4 inhibitors obtained through fragment-based drug de...
The phosphodiesterase 4 (PDE4) family of enzymes is a promising drug target for a variety of conditi...
A number of novel imidazophenoxazine-4-sulfonamides have been designed as potential inhibitors of PD...
A new series of 3-(cyclopentyloxy)-4-methoxyphenyl derivatives, structurally related to our hit GEBR...
PDE4 inhibitors have been identified as therapeutic targets in a variety of conditions, particularly...
The phosphodiesterase 4 (PDE4) enzyme, which is responsible for hydrolyzing cAMP in immune cells and...
Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of an...
Novel polysubstituted pyrroles have been designed and accessed via a one-pot multicomponent reaction...
The phosphodiesterase 4 (PDE4) enzyme, which is responsible for hydrolyzing cAMP in immune cells and...
In this study, a series of pyrazole derivatives containing 4-phenyl-2-oxazole moiety were designed a...
A number of novel 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles based on a conform...
<p>cAMP, intracellular cyclic adenosine monophosphate, is a ubiquitous second messenger that plays a...
A series of novel hybrid molecules were designed rationally by connecting an indole moiety with a q...
AbstractA series of novel hybrid molecules were designed rationally by connecting an indole moiety w...
The design, synthesis, and biological evaluation of new phosphodiesterase type 4 (PDE4) inhibitors, ...
We report here a new series of quinolines as PDE4 inhibitors obtained through fragment-based drug de...
The phosphodiesterase 4 (PDE4) family of enzymes is a promising drug target for a variety of conditi...
A number of novel imidazophenoxazine-4-sulfonamides have been designed as potential inhibitors of PD...
A new series of 3-(cyclopentyloxy)-4-methoxyphenyl derivatives, structurally related to our hit GEBR...
PDE4 inhibitors have been identified as therapeutic targets in a variety of conditions, particularly...
The phosphodiesterase 4 (PDE4) enzyme, which is responsible for hydrolyzing cAMP in immune cells and...
Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of an...
Novel polysubstituted pyrroles have been designed and accessed via a one-pot multicomponent reaction...
The phosphodiesterase 4 (PDE4) enzyme, which is responsible for hydrolyzing cAMP in immune cells and...
In this study, a series of pyrazole derivatives containing 4-phenyl-2-oxazole moiety were designed a...
A number of novel 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles based on a conform...
<p>cAMP, intracellular cyclic adenosine monophosphate, is a ubiquitous second messenger that plays a...